Vanke proposes extension for $986m onshore bonds

Use the previous and next buttons or keyboard arrows to navigate between slides.

News & Analysis

LevFin

Vitamin Well docs drop lawyer DQ list after attempting European first

Lenders successfully pushed back against a controversial disqualified counsel restriction in Vitamin Well’s docs, according to 9fin sources. High watermarking was also removed from the docs, sources added.

22 Jul 2026

| Europe

News & Analysis

Investment Grade

LevFin

Sustainable Junk — GSSS volumes roar back; EuGB take-up doesn't

Green, social, sustainable, and sustainability-linked (GSSS) debt issuance across international syndicated markets staged its strongest quarter in two years in Q2 2026, but the recovery was uneven across regions. Western Europe saw a rally and there was a modest revival in North America, while LatAm GSSS issuance underwent a severe decline.

22 Jul 2026

| Global

News & Analysis

LevFin

Cinven and Bridgepoint attempt Europe’s first lawyer DQ list via Vitamin Well

Docs for Cinven and Bridgepoint-backed Vitamin Well’s dual-tranche TLB deal include a disqualified counsel list (lawyer DQ list) in any potential restructuring, according to 9fin sources — the first time this has been attempted in Europe, having appeared in the US nearly a year ago.

21 Jul 2026

| Europe

News & Analysis

LevFin

Skim yields — Chobani’s credit glow-up leaves lenders asking what’s left to buy

When Hamdi Ulukaya bought an old yogurt plant in upstate New York two decades ago, Greek yogurt was just a specialty item in the grocery store.

20 Jul 2026

| US

News & Analysis

ABF

LevFin

Brookfield, Tor join PaleBlueDot’s $255m GPU-backed private note

PaleBlueDot AI has closed a $255m GPU-backed three-year private note, 9fin sources said. Brookfield and Tor Investment Management were among the investors, according to the sources. JP Morgan acted as lead manager for the facility.

20 Jul 2026

| APAC

News & Analysis

Distressed

LevFin

High stakes — Rescheduling to test cannabis borrowers

In the world of leveraged finance, operating without the ability to deduct SG&A expenses from taxes is a total nonstarter. But for US cannabis companies — particularly those on the adult-use recreational side — such a move currently remains out of reach.

17 Jul 2026

| US